Targeting Innovation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

Arrowhead's pipeline is intended to drive value directly through the clinical development process and to provide proof of concept for the platform technologies. We actively seek collaboration and licensing agreements with leading biopharmaceutical companies to advance the development and commercialization of our technology platforms and drug candidates. Partnerships provide access external expertise and capital to complement our internal research and create commercialization opportunities in areas outside of our core focus.

Lead Products

  • ARC-520, an RNAi-based therapeutic that targets the hepatitis B virus for the treatment of chronic Hepatitis B.
  • Adipotide®, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue.

Platform Technologies

The modular and synergistic design of each platform provides a broad base for the development of further products.

  • Dynamic Polyconjugates™, a best-in-class small RNA delivery system that has been demonstrated to promote efficient knockdown and wide safety margins using a variety of siRNA molecules.
  • Homing Peptides™, a vast, proprietary library of peptides that have been shown to distinctly target nearly every tissue in the human body.


Arrowhead is headquartered in Pasadena, CA and operates a 24,000 square foot research and development facility located in Madison, WI. Arrowhead's team consists of approximately 50 full time management and technical employees with deep expertise in drug development and commercialization. This team is augmented by an accomplished Board of Directors and world-class scientific and clinical advisors.